

Immunohistochemical Detection of Epidermal Growth Factor Receptor (EGFR) Expression in Colorectal Adenocarcinomas

INTRODUCTION


- FDA approved test used to identify colorectal cancer patients eligible for treatment with Erbitux (Cetuximab) or Vectibix (panitumumab), monoclonal antibodies that bind to EGFR to inhibit its tyrosine kinase activity
- A semi-quantitative immunohistochemical assay using EGFR PharmDx, a trademark of DAKO Cytomation

INDICATION

Advanced colorectal cancer that has spread to other parts of the body

SPECIMEN REQUIREMENTS

Formalin-fixed, paraffin-embedded tissue sections or blocks containing tumor cells



EGFR staining in colorectal carcinoma

Contact information:

Department of Pathology and Laboratory Medicine
8700 Beverly Blvd. Suite 8709, Los Angeles, CA 90048
(310) 423-6611 Tel; (310) 423-0122 Fax

Diagnosis at the Speed of Right